Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
| ▸ | PDE4A | P27815 | 4/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 4/20 | 0.35 |
| ▸ | BRD2 | P25440 | 2/20 | 0.35 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.35 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8043797 | 0.77 | GDA (0.36) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22326779 | 0.74 | ALDH1A1 (0.34) | ADORA2APDE4BSMN1; SMN2RAB9APOLB | |
| SCHEMBL23679501 | 0.74 | SLC2A1 (0.33) | ADORA2APDE4BSMN1; SMN2RAB9APOLB | |
| SCHEMBL18520821 | 0.73 | SMN1; SMN2 (0.40) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21637050 | 0.73 | TDP1 (0.37) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13181197 | 0.73 | SMN1; SMN2 (0.38) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18521156 | 0.71 | PNP (0.45) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23228226 | 0.71 | BRD4 (0.39) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22883503 | 0.71 | SLC2A1 (0.33) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL23867234 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20200331957-A1 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | AJ SCIENCES (YIXING) CO., LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| WO-2020117624-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2019043634-A2 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2019-03-07 | — | — | WO | disclosed |
| WO-2018118664-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331957-A1 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | STING1, IRF3, CGAS | ADORA2A 216/4885PDE4A 30/4885PDE4B 72/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | ADORA2A 216/4885PDE4A 30/4885PDE4B 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.